Danske Bank’s Allarity Therapeutics ALLR Stock Holding History

Danske Bank’s Portfolio ALLR Stock Details ALLR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1	Hold	1	–	–	﹤0.01%	1137
2026 Q2	$1	Hold	1	–	–	﹤0.01%	1131
2026 Q1	$1	Hold	1	–	–	﹤0.01%	1156
2025 Q4	$1	Hold	1	–	–	﹤0.01%	1545
2025 Q3	$2	Hold	1	–	–	﹤0.01%	1462
2025 Q2	$1	Hold	1	–	–	﹤0.01%	1507
2025 Q1	$1	Hold	1	–	–	﹤0.01%	1353
2024 Q4	$1	Sell	1 -7	-88%	-$9	﹤0.01%	1391
2024 Q3	$17	Buy	+8	New	+$38	﹤0.01%	1503

Other funds holding ALLR

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Danske Bank's ALLR Position: Q3 2026 in Review

Danske Bank held its Allarity Therapeutics (ALLR) position steady in Q3 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

Danske Bank first reported a position in ALLR in Q3 2024 and has held it in 9 quarters since. The position peaked at $17 in Q3 2024. 6 funds tracked by Wall St. Rank hold ALLR as of Q3 2026.

Danske Bank held 1 share of Allarity Therapeutics worth $1 as of Q3 2026.
Danske Bank left its Allarity Therapeutics share count unchanged in Q3 2026.
Allarity Therapeutics made up ﹤0.01% of Danske Bank's portfolio in Q3 2026, its #1137 holding.
Danske Bank first reported a position in Allarity Therapeutics in Q3 2024 and has held it in 9 quarters since.
Danske Bank's Allarity Therapeutics position peaked at $17 in Q3 2024.
6 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q3 2026.

Based on Danske Bank's 13F filing for Q3 2026, filed 9 Nov 2026.